1. Alberta Medical Association. Guideline for adult primary insomnia: assessment to diagnosis. Alberta Medical Association. 2010. (Accessed October 2014). Open link »
  2. Allain H et al. Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging 2005; 22: 749-765.
  3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Ed. Washington DC: American Psychiatric Association. 2013. Open link »
  4. American Psychiatric Association. Sleep disorders. In: Diagnostic and Statistical Manual of Mental Disorders, Fourth Ed. Washington DC: American Psychiatric Association. 2000. Open link »
  5. Arroll, B., Ferdando, A., Falloon, K. et al. Sleepless in Seattle? Finding patients with primary insomnia using the Auckland Sleep Questionnaire. North American Primary Care Research Group Seattle 2010.
  6. Ashton, H. The diagnosis and management of benzodiazepine dependence. Current Opinion in Psychiatry 2005; 18; 249-255.
  7. Bain KT. Management of chronic insomnia in elderly persons. Am J Geriatr Pharmacother. 2006; 4: 168–192.
  8. Bixler EO, Papaliaga MN, Vgontzas AN, Lin HM, Pejovic S, Karataraki M, et al. Women sleep objectively better than men and the sleep of young women is more resilient to external stressors: effects of age and menopause. J Sleep Res 2009; 18: 221–228.
  9. Bloch F, Thibaud M, Dugue B, Breque C, Rigaud A-S, Kemoun 
G. Psychotropic drugs and falls in the elderly people: updated literature review and meta-analysis. J Aging Health. 2011; 23(2): 329–46.
  10. BNF for Children November 2014. Accessed October 2014.
  11. BNF No. 65 (March-September 2014). Accessed October 2014.
  12. British Geriatrics Society. Fit for Frailty - consensus best practice guidance for the care of older people living in community and outpatient settings - a report from the British Geriatrics Society 2014.
  13. Brunton L, Goodman L, Blumenthal D, et al. Goodman and Gilman’s Manual of Pharmacology and Therapeutics. USA: Mcgraw Hill Companies, 2008: 262-79.

  14. Budur K, Rodriguez C, Foldvary-Schaefer N. Advances in treating insomnia. Cleveland Clin J Med 2007; 74: 251–266.
  15. Buscemi N, Vandermeer B, Friesen C et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med 2007; 22: 1335–1350.
  16. Buysse DJ. Insomnia. JAMA 2013; 309: 706–716.
  17. Care Quality Commission. Intelligent Monitoring. NHS GP practices – Indicators and methodology. December 2014. Accessed December 2014. Open link »
  18. Centre for sleep. Clinical practice guideline – Adult insomnia: Assessment to diagnosis. 2007. (Accessed October 2014).
  19. Circadin SPC (Accessed October 2014). Open link »
  20. CSM. Current Problems Pharmacovigilance. January 1988, No. 21. (Accessed October 2014).
  21. Daley M, Morin CM, LeBlanc M, Gregoire JP, Savard J and Baillargeon L. Insomnia and its relationship to health-care utilization, work absenteeism, productivity and accidents. Sleep Med 2009; 10: 427–438.
  22. Driver and Vehicle Licensing Agency 2013. At a glance guide to the current medical standards of fitness to drive. Open link »
  23. Falloon K, Arroll B, Elley CR, Fernando 3rd A. The assessment and management of insomnia in primary care. BMJ 2011; 342: d2899.
  24. Glass J, Lanctot KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005; 331:1269-1276.
  25. Glass J, Lanctot KL, Herrmann N, Sproule BA and Busto UE. Sedative hypnotics in older people with insomnia: metaanalysis of risks and benefits. Br Med J. 2005; 331: 1169.
  26. GMC. Good Practice in Prescribing Medicines. September 2008.
  27. Gottesmann, C. GABA mechanisms and sleep. Neuroscience 2002; 111(2): 231-9.

  28. Gustavsen I, et al. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med 2008; 9: 818-822.
  29. Gustavsen I, et al. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med 2008; 9: 818-922.
  30. Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists. Neuropsychiatr Dis Treat 2009:5;341-54.

  31. Hartikaenen S, Lonnroos E, Louhivuori K. Medication as a Risk Factor for Falls: Critical Systematic Review. Jnl Gerontol 2007; 62A (10): 1172-1181.
  32. Hartmann E, Cravens J. The effects of long-term administration of psychotropic drugs on human sleep: V. The effects of chloral hydrate. Psychopharmacologia 1973; 33(3): 219-32.

  33. Holbrook A.M, Crowthe, R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. Canadian Medical Association Journal 2000: 162; 225-233.
  34. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. The diagnosis and management of insomnia in clinical practice: a practical evidence-based approach. Can Med Assoc J 2000; 162: 216–220.
  35. Irwin MR, Cole JC and Nicassio PM. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age. Health Psychol. 2006; 25: 3–14.
  36. Joint Formulary Committee. British National Formulary for Children March 2013 (online) London: BMJ Group and Pharmaceutical Press
  37. Katz DA and McHorney CA. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract 2002; 51: 229–235.
  38. Kripke 0, et al. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open Feb 2012.
  39. Leersnyder, H et al. Prolonged-release melatonin for children with neurodevelopmental disorders. Pediatric Neurology 2011; 45: 23-26.
  40. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriat Soc 1999; 47(1): 30-39.
  41. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007; 16: 372-380.
  42. London Procurement Partnership, Medicines Use & Procurement Productivity Workstream. Choosing between melatonin formulations for treatment of sleep disorders. July 2013.
  43. Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol 2009; 24: 239-249.
  44. Malow BA, Adkins KW, McGrew SG, Wang L, Goldman SE, PhD1, Fawkes D, Burnette C. Melatonin for Sleep in Children with Autism: A Controlled Trial Examining Dose, Tolerability, and Outcomes. J Autism Dev Disord. 2012; 42(8): 1729–1737.
  45. MHRA Guidance Note 14. Summary of notifications for Importation of Unlicensed Medicines (Accessed October 2014).
  46. MHRA. Addiction to benzodiazepines and codeine; supporting safer use. Drug Safety Update, July 2011.
  47. MHRA. Off-label or unlicensed use of medicines: prescribers’ responsibilities. MHRA. Drug Safety Update. Volume 2, Issue 9. April 2009. (Accessed October 2014).
  48. MHRA. Restrictions on the import of unlicensed Melatonin products following the grant of a marketing authorisation for Circadin ® 2mg tablets. MHRA Drug procurement advice. 2008. (Accessed October 2014).
  49. Mindell JA, Kuhn B, Lewin DS, Meltzer LJ and Sadeh A. Behavioral treatment of bedtime problems and night wakings in infants and young children. Sleep 2006; 29: 1263–1276.
  50. Montgomery P, Dennis J. Cognitive behavioural interventions for sleep problems in adults aged 60+. Cochrane Library. Oxford: Update Software; 2002.
  51. Montplaisir J, Hawa R, Moller H, Morin C, Fortin M, Matte J, et al. Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Hum Psychopharmacol Clini Exp 2003; 18: 29–38.
  52. Morin CM, Bootzin DJ, Edinger JD, et al. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004). Sleep 2006; 29: 1398–1414.
  53. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial [comment]. JAMA 1999; 281: 991–999.
  54. Morin CM. Insomnia, Psychological Assessment and Management. New York, NY: The Guilford Press. 1993.
  55. Morphy, H., Dunn, K.M., Boardman, H.F. and Croft, P.R. Epidemiology of insomnia: a longitudinal study in a UK population. Sleep 2007; 30: 274-280.
  56. MTRAC. Commissioning Support Melatonin (Circadin®) for the treatment of primary insomnia. Midlands Therapeutics Review & Advisory Committee (MTRAC), Centre for Medicines Optimisation, Keele University. October 2013. (Accessed October 2014). Open link »
  57. National Institutes of Health 2005. NIH State-of-the-Science conference statement on manifestations and management of chronic insomnia in adults. (Accessed October 2014).
  58. National Pharmacy Association. Use of unlicensed medicines: information factsheet. September 2010.
  59. NHS Business Services Authority. Prescription Cost Analysis Data. October 2014 data. (Accessed February 2015).
  60. NICE Clinical Knowledge Summary. Benzodiazepine and z-drug withdrawal. July 2013. (Accessed October 2014). Open link »
  61. NICE Clinical Knowledge Summary. Insomnia. Last revised in June 2014. (Accessed October 2014). Open link »
  62. NICE. Falls: assessment and prevention of falls in older people. NICE CG161. National Institute for Health and Care Excellence. June 2013. (Accessed October 2014). Open link »
  63. NICE. Guidance on the use of zaleplon, zolpidem and zopliclone for the short-term management of insomnia (NICE technology appraisal 77). National Institute for Health and Care Excellence. 2004. (Accessed October 2014). Open link »
  64. NICE. Key therapeutic topics - Medicines management options for local implementation. Updated January 2013. (Accessed October 2014). Open link »
  65. NICE. Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin. NICE advice ESUOM2. January 2013. (Accessed October 2014). Open link »
  66. Nolen TM. Sedative effects of antihistamines: safety, performance, learning and quality of life. Clin Therapeutics 1997; 19: 39-55.

  67. Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep 2004; 27: 1255–1273.
  68. Otmani S, Metzger 0, Guichard N et al. Effects of prolonged release melatonin and zolpidem on postural stability in older adults. Hum Psychopharmacol Clin Exp 2012: 27: 270–276.
  69. Paul MA, Gray G, Sardana TM and Pigeau RA. Melatonin and Zopiclone as Facilitators of Early Circadian Sleep in Operational Air Transport Crews. Aviation, Space and Environmental Medicine. 2004: 75; 439-443.
  70. Perlis ML, Smith MT, Cacialli DO, Nowakowski S, Orff H. On the comparability of pharmacotherapy and behavior therapy for chronic insomnia: commentary and implications. J Psychosom Res 2003; 54: 51–59.
  71. Pharmacy Professional. Dealing with Specials. Good practice guidance on the procurement and supply of pharmaceutical specials. Royal Pharmaceutical Society, June 2010. Open link »
  72. Prescribing and Primary Care team, Health and Social Care Information Centre. Prescription Cost Analysis England 2012 V1.0. 04/04/2013.
  73. Ramakrishnan K and Scheid D.C. Treatment options for insomnia. American Family Physician2007: 76; 5-526.
  74. Ramchandani P, Wiggs L, Webb V and Stores G. A systematic review of treatments for settling problems and night waking in young children. Br Med J 2000; 320: 209–213.
  75. Rhalimi M, Helou R and Jaecker P. Medication use and increased risk of falls in hospitalized elderly patients: a retrospective, case-control study. Drugs Aging 2009; 26: 847–852.
  76. Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long- term therapeutic use of benzodiazepines: I. Effects of abrupt discontinuation. Archives of General Psychiatry 1990; 47(10): 899–907.
  77. Riemann D. Does effective management of sleep disorders reduce depressive symptoms and the risk of depression? Drugs 2009; 69(Suppl 2): 43–64.
  78. Ringdahl EN, Pereira SL, Delzell JE. Treatment of primary insomnia. J Am Board Fam Pract 2004; 17: 212–219.
  79. Roth T. Sleep Medicine Clinics: Insomnia. Volume 1, Number 3. Philadelphia: WB Saunders. 2006.
  80. Royal College of Paediatrics and Child Health Medicines for Children. Melatonin for sleep disorders - Patient Information Leaflet. (Accessed October 2014). Open link »
  81. Royal Pharmaceutical Society. Medicines Optimisation: Helping patients to make the most of medicines. Royal Pharmaceutical Society 2013. (Accessed October 2014). Open link »
  82. Samuels C, Khullar A, Fraser K, Moroz T, Askin J, Brandon T, et al. Management of Chronic Insomnia in Primary Care: Academic detailing. Alberta Health Services and the University of Calgary. May 2009.
  83. Sateia M and Nowell P.D. Insomnia. Lancet 2004; 364, 1959-1973.
  84. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008; 4: 487–504.
  85. Simon, G.E. and VonKorff, M. Prevalence, burden, and treatment of insomnia in primary care. American Journal of Psychiatry 1997; 154: 1417-1423.
  86. Siriwardena AN, et al. Magic Bullets for insomnia? Patients' use and experiences of newer (Z drugs) versus older (benzodiazepine) hypnotics for sleep problems in Primary Care. Br J Gen Pract 2008; 58: 417-422.
  87. Sleep-Wake disorders. American Psychiatric Association. 2013. (Accessed October 2014). Open link »
  88. Smith MT, Perlis ML, Park A, Smith MS, Pennington J, Giles DE, et al. Comparative meta-analysis of pharmacotherapy and behaviour therapy for persistent insomnia. Am J Psychiatry 2002; 159: 5–11.
  89. Tamanna S, Geraci SA. Major sleep disorders among women. South Med J. 2013; 106(8): 470-478
  90. The National Addiction Centre, King’s College London, and School of Social and Community Medicine, University of Bristol, 2011. The changing use of prescribed benzodiazepines and z-drugs and of over-the-counter codeine-containing products in England: a structured review of published English and international evidence and available data to inform consideration of the extent of dependence and harm.
  91. Unruh ML, Redline S, An MW, Buysse DJ, Nieto FJ, Yeh JL, et al. Subjective and objective sleep quality and aging in the sleep heart health study. J Am Geriatr Soc 2008; 56: 1218–1227.
  92. Uzun S, Kozumplik O, Jakovljevic M, Sedic B. Side effects of treatment with benzodiazepines. Psychiatria Danubina 2010; 22(1): 90–3.
  93. van Geijlswijk IM, van der Heijden KB, Egberts AC, Korzilius HP, Smits MG. Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCT. Psychopharmacology 2010; 212: 379–391.
  94. Wade AG et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med 2010; 8: 51.
  95. Wade AG, Ford I, Crawford G et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007; 23: 2597-2605.
  96. Weich S, Pearce H, Croft P, Singh Swaran, Crome I, Bashford J, Frisher M. Effect of Anxiolytic and Hypnotic Drug Prescriptions on Mortality Hazards: Retrospective Cohort Study. BMJ 2014; 348: g1996. doi: 10.1136/bmj.g1996 Open link »
  97. Wilson, S.J., Nutt, D.J., Alford, C. et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. Journal of Psychopharmacology 2010; 24; 1577-1601.
  98. Woolcott J. et al. Meta-analysis of the impact of 9 medical classes on falls in elderly persons. Arch Intern Med 2009; 23; 169: 1952-1960.
  99. Zhdanova I, Wurtman R, Regan M, et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001; 86(10): 4727-30.
  100. Zint K, Haefeli WE, Glynn RJ, Mogun H, Avorn J, Sturmer T. Impact of drug interactions, dosage, and duration
of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiology and drug safety 2010; 19(12): 1248–55.

School of Pharmacy and Bioengineering,
The Hornbeam, Keele University,
Keele, Staffordshire, ST5 5BG.

T: 01782 479790

© 2015 Keele University, © 2015 PDS Ltd

Supported by an unrestricted grant
from Flynn Pharma Ltd in the UK.

Flynn Pharma